Bessemer Group Inc Exact Sciences Corp Transaction History

Bessemer Group Inc

$61.3 Billion
Q4 2024

A detailed history of Bessemer Group Inc transactions in Exact Sciences Corp stock. As of the latest transaction made, Bessemer Group Inc holds 21 shares of EXAS stock, worth $1,034. This represents 0.0% of its overall portfolio holdings.

Number of Shares

Holding current value

$1,034

% of portfolio

0.0%

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 13, 2025	BUY	$49.33 - $71.97 $1,035 - $1,511	21 New	21 $1,000
Q3 2023 Nov 13, 2023	BUY	$65.94 - $99.04 $329 - $495	5 New	5 $0
Q1 2022 May 12, 2022	SELL	$57.56 - $82.54 $16,174 - $23,193	-281 Closed	0 $0
Q4 2020 Feb 09, 2021	BUY	$99.61 - $142.12 $27,990 - $39,935	281 New	281 $37,000
Q1 2020 Apr 30, 2020	SELL	$37.9 - $104.44 $1,516 - $4,177	-40 Closed	0 $0
Q2 2019 Jul 19, 2019	SELL	$89.51 - $118.04 $95,149 - $125,476	-1,063 Reduced 96.37%	40 $5,000
Q4 2018 Feb 12, 2019	BUY	$56.04 - $82.66 $5,772 - $8,513	103 Added 10.3%	1,103 $69,000
Q2 2018 Jul 25, 2018	SELL	$37.84 - $69.96 $37,840 - $69,960	-1,000 Reduced 50.0%	1,000 $60,000
Q3 2017 Nov 03, 2017	BUY	$37.05 - $47.12 $74,100 - $94,240	2,000	2,000 $94,000

Others Institutions Holding EXAS

# of Institutions

672

Shares Held

164M

Call Options Held

4.25M

Put Options Held

1.89M

Capital World Investors Los Angeles, CA

17.5M
Shares

$864 Million
0.16% of portfolio
Vanguard Group Inc Valley Forge, PA

17M
Shares

$838 Million
0.02% of portfolio
Black Rock Inc. New York, NY

12.1M
Shares

$594 Million
0.01% of portfolio
Wellington Management Group LLP Boston, MA

12.1M
Shares

$594 Million
0.13% of portfolio
State Street Corp Boston, MA

6.23M
Shares

$307 Million
0.01% of portfolio

View Full List

About EXACT SCIENCES CORP

Ticker EXAS
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 176,960,000
Market Cap $8.72B
Description
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for...

More about EXAS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Bessemer Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Bessemer Group Inc with notifications on news.

Account